Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

d explanation is lack of specificity of Trasylol®.

TXA and EACA are lysine analogs that function as competitive inhibitors of plasminogen activation and, at much higher concentrations, noncompetitive inhibitors of plasmin.  These agents are considered to be safer but less effective than Trasylol®. While TXA is approximately 10 times more potent than EACA, it is associated with a fourfold increase over EACA in the risk of seizures.  Further, a study demonstrated that patients administered TXA required more transfusion product than patients who were administered Trasylol®, resulting in significantly higher overall transfusion-related costs for patients treated with the less expensive, generic agent TXA.  

Omeros' proprietary antifibrinolytic agents are highly selective inhibitors of plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of Factor XIa and kallikrein. This selectivity could provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immunological side effects.

About Omeros' Antifibrinolytic Program

Omeros is developing a series of novel antifibrinolytic agents for the control of blood loss during surgery or resulting from trauma. Omeros' agents are designed to selectively inhibit plasmin, the enzyme responsible for fibrinolysis and dissolving blood clots, while avoiding significant inhibition of Factor XIa and kallikrein, important regulators of the coagulation cascade. These agents could provide a superior replacement for the antifibrinolytic agents Trasylol® (aprotinin), tranexamic acid and epsilon aminocaproic acid. The selectivity of Omeros' agents may provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immuno
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... YORK , Sept. 29, 2014 EU5 ... Summary GlobalData,s new report, "EU5 Capsule ... data on the EU5 Capsule Endoscopy Systems market. The ... (in units) and average prices (in US dollars) within ... and Capsule Endoscopy Workstations. The report also ...
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and ... that could reduce prescription fraud and abuse in Medicare ... Opioid Abuse: Fighting Back on Many Fronts ," sponsored ... The briefing featured several government and industry ... fraud. The Centers for Disease Control and Prevention has ...
(Date:9/29/2014)... LAKE CITY , Sept. 29, 2014 /PRNewswire/ ... has scheduled a conference call for investors today ... for the quarter and year ended June 30, ... in participating is (800) 771-7941. Dynatronics ... soft goods and supplies, treatment tables and rehabilitation ...
Breaking Medicine Technology:EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ) today ... on Wednesday, August 3 at 4:30 p.m. Eastern Time to discuss ... follow the release of the second quarter financial results after market ... To access the live conference call on August 3 at ...
... July 27, 2011 For men facing radical prostatectomy ... not their only concern. In fact, a large number of ... continence among their biggest fears. More than 240,000 men will ... patients of Dr. David Samadi,s, Vice Chairman, Department of Urology, ...
Cached Medicine Technology:Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 2Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 3Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 2Post Robotic Prostate Surgery Continence and Pelvic Floor Muscles 3
(Date:9/30/2014)... Dennis Thompson HealthDay Reporter ... day, people receive medical implants -- artificial valves, hip ... have been rigorously tested before or after their approval by ... The studies -- conducted by prominent nonprofit groups and ... -- lay the blame for inadequate medical device testing on ...
(Date:9/30/2014)... 30, 2014 Houstonians seeking the latest ... to visit on the Internet. Paul Vitenas, JR. ... respected cosmetic surgeons, has launched a new website to ... of Botox Cosmetic services. The new website ... According to the new website, Botox Cosmetic is a ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Neuromuscular ... people throughout the United States and worldwide. It ... Disease are diagnosed each year, adding to the ... the disease. Approximately 400,000 people in the US ... worldwide. Add to these statistics the 2.4 percent ...
(Date:9/30/2014)... Gummy teeth treatment expert, ... for dark gums. Dark gums are usually considered a ... self-conscious about their smiles. Dr. Farnoosh has pioneered a ... one of the few dental professionals nationwide offering black ... business leaders, high-ranking officials and patients from all over ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Herceptin is the best ... HER2-positive and should remain the standard of care for ... a long-term clinical trial. HER2-positive breast cancers tend ... cancer, according to the Mayo Clinic. For the ... either Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... (CLP) at Thomas Jefferson University Hospital, recently received an ... scope of the normal duties of serving as ... American College of Surgeons Commission on Cancer (CoC). ... appointment and is among a national network of over ...
... ... Use Dashboard will provide a single location where an organization can see, at a ... ... 2010 -- Health Care DataWorks , a Technology Company created to commercialize the ...
... finds they are equal to artery-clearing surgery, but another ... -- Both stents and conventional surgery appear to be ... arteries are blocked, according to research presented Friday at ... , However, a second stents-versus-surgery trial, published Thursday in ...
... ... company, has signed a strategic partnership agreement with Medical Insight to complete the ... capability across the healthcare enterprise. , , ... Milwaukee (PRWEB) February 26, 2010 -- ...
... The natural-occurring biopolymer known as chitosan is being put ... the diet of ruminants, according to research carried out ... presence of these antibiotics as additives in the diet ... since 2006, given that their use is linked to ...
... ... ... ... ...
Cached Medicine News:Health News:Jefferson surgeon receives outstanding performance award from American College Of Surgeons 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2Health News:Stents May Be Effective Weapon Against Stroke 2Health News:Stents May Be Effective Weapon Against Stroke 3Health News:Stents May Be Effective Weapon Against Stroke 4Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 2Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 3Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 2Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 2Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 4Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 5
Manufactured with large, shatter-resistant Clear Pb leaded acrylic panels which provide a wide field of vision for one or more users. Opaque lower panels are covered in your choice of decorative viny...
... Excellent for patient protection ... erect chest and cervical spine. ... 0.5mm shield. Height adjustable 36" ... sturdy star-leg aluminum base for ...
RayShield Frame Mounted Overhead Lead Acrylic Barriers are offered in a choice of three sizes: 60 cm x 80 cm ( 24" x 32") wide, 60 cm x 50 cm( 24" x 20") wide. Lead acrylic windows of 0.5 mm and 1.0 ...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
Medicine Products: